Siemens Healthineers has plans to unveil its Symbia Intevo Bold SPECT/CT at the Society of Nuclear Medicine & Molecular Imaging annual meeting in Denver this weekend.

In recent years, the PET/CT market has experienced substantial growth. The SPECT/CT market is now on a similar track, as more facilities are starting to use the modality as standalone or back-up diagnostic CT systems.

These facilities want to acquire SPECT and CT images on the same system in order to more efficiently care for SPECT patients who also require a diagnostic CT scan. Because of that, SPECT/CT systems with advanced CT capabilities are in demand.
Siemens designed the Symbia Intevo Bold SPECT/CT with those market demands in mind. A variety of optional applications that enhance the CT capabilities are offered to customers when purchasing the system.

This is the first Siemens SPECT/CT system equipped with the company’s Sinogram Affirmed Iterative Reconstruction (SAFIRE) and Iterative Metal Artifact Reduction (iMAR) algorithms.

The SAFIRE algorithm helps the system achieve excellent CT image quality, lessen noise while maintaining detail visualization, and reduce the radiation dose administered to patients by up to 60 percent. It can be easily integrated into a facility’s clinical routine because of its fast image reconstruction.

The iMAR algorithm reduces artifacts caused by metallic materials like dental or orthopedic implants. This also allows users to apply the CT images for attenuation correction in order to get a better quality and more accurate SPECT image.

The optional interleaved volume (IVR) feature reconstructs overlapping CT images up to 32 slices to extract the largest amount of diagnostic information, so that small lesions or fractions can be evaluated. It also improves spatial resolution in the z-direction of all CT scans, regardless of pitch.

The Symbia Intevo Bold deploys two sequential spiral CT scans that operate at different kV levels to combine tissue information with disease morphology. Post-processing applications are also available with the syngo Dual Energy software including monoenergetic, Calculi Characterization and gout.

The system also offers advanced SPECT capabilities, such as the xSPECT Quant quantification technology. It automatically quantifies Technetium-99m, Iodine-123, Lutetium-177 and Indium-111, which enables the system to be used for neurological disorders, neuroendocrine tumors and prostate cancer.

Back to HCB News

CT Homepage